

<b>General information about company</b>	
Scrip code	532843
NSE Symbol	FORTIS
MSEI Symbol	NOTLISTED
ISIN	INE061F01013
Name of the entity	Fortis Healthcare Limited
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Reporting Quarter Type	Yearly
Date of Quarter Ending	31-03-2026
Type of company	Equity
Whether Annexure I (Part A) of the SEBI Circular dated December 31, 2024 related to Compliance Report on Corporate Governance is applicable to the entity?	Yes
Whether Annexure I (Part B) of the SEBI Circular dated December 31, 2024 related to Investor Grievance Redressal Report is Applicable to the entity?	Yes
Whether Annexure I (Part C) of the SEBI Circular dated December 31, 2024 related to Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies is Applicable to the entity?	No There was no acquisition of shares or voting rights in Unlisted Companies during the Quarter and year ended March 31, 2026. However, the company through its wholly owned subsidiary i.e. International Hospital Limited (IHL) had executed definitive agreements on December 19, 2025, at 11:25 PM (IST) for the acquisition of 100% stake of TMI Healthcare Private Limited through a Share Purchase Agreement. The said transaction was disclosed to the stock exchanges on December 20, 2025. The acquisition was subsequently consummated and was reported to the stock exchange on January 9, 2026
Whether Annexure I (Part D) of the SEBI Circular dated December 31, 2024 related to Disclosure of Imposition of Fine or Penalty is Applicable to the entity?	Yes
Whether Annexure I (Part E) of the SEBI Circular dated December 31, 2024 related to Disclosure of Updates to Ongoing Tax Litigations or Disputes is Applicable to the entity?	Yes
Whether Annexure I (Part F) of the SEBI Circular dated December 31, 2024 related to Disclosure Of Loans / Guarantees / Comfort Letters / Securities Etc. is Applicable to the entity?	Yes
Risk management committee	Applicable
Market Capitalisation as per immediate previous Financial Year	Top 500 listed entities
Is SCORE ID Available ?	Yes
SCORE Registration ID	f00057
Reason For No SCORE ID	
Type of Submission	Original
Remarks (website dissemination)	
Remarks for Exchange (not for Website Dissemination)	

**Annexure I****Annexure I to be submitted by listed entity on quarterly basis****I. Composition of Board of Directors**

Disclosure of notes on composition of board of directors explanatory

Whether the listed entity has a Regular Chairperson Yes

Whether Chairperson is related to MD or CEO No

Sr	Title (Mr / Ms)	Name of the Director	PAN	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of Birth
1	Mr	Leo Puri	AALPP0852A	01764813	Non-Executive - Independent Director	Chairperson		03-01-1961
2	Mr	Indrajit Banerjee	ADVPB8026B	01365405	Non-Executive - Independent Director	Not Applicable		14-01-1956
3	Mr	Ashutosh Raghuvanshi	ACBPA0998E	02775637	Executive Director	Not Applicable	CEO-MD	11-08-1962
4	Ms	Suvalaxmi Chakraborty	AADPC2775K	00106054	Non-Executive - Independent Director	Not Applicable		22-07-1966
5	Mr	Dilip Kadambi	AEGPK9884A	02148022	Non-Executive - Non Independent Director	Not Applicable		02-08-1974
6	Mr	Ashok Pandit	AAJPP2294C	09279899	Non-Executive - Non Independent Director	Not Applicable		24-12-1965
7	Mr	Prem Kumar Nair	ZZZZZ9999Z	10348774	Non-Executive - Non Independent Director	Not Applicable		25-08-1960
8	Mr	Keith Hsiu Chin Lim	ZZZZZ9999Z	11276851	Non-Executive - Non Independent Director	Not Applicable		21-05-1974
9	Mr	Mohd Shahazwan Bin Mohd Harris	ZZZZZ9999Z	08465456	Non-Executive - Non Independent Director	Not Applicable		24-12-1971

**I. Composition of Board of Directors****Disqualification of Directors under section 164 of the Companies Act, 2013**

Sr	Whether the director is disqualified?	Start Date of disqualification	End Date of disqualification	Details of disqualification	Current status
1	No				Active
2	No				Active
3	No				Active
4	No				Active
5	No				Active
6	No				Active
7	No				Active
8	No				Active
9	No				Active

**I. Composition of Board of Directors**

Sr	Whether special resolution passed? [Refer Reg. 17(1A) of Listing Regulations]	Date of passing special resolution	Initial Date of appointment	Date of Re-appointment	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 17A of Listing Regulations)	No of Independent Directorship in listed entities including this listed entity [with reference to proviso to regulation 17A(1) & reg. 17A(2)]	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)	Reason for Cessation	Notes for not providing PAN	Notes for not providing DIN
1	NA		27-12-2024			16	2	2	1	1			
2	NA		27-04-2018	27-04-2023		95	2	2	5	3			
3	NA		19-03-2019	19-03-2025			1	0	1	0			
4	NA		27-04-2018	27-04-2023		95	2	2	4	3			
5	NA		04-06-2020				1	0	0	0			
6	NA		13-09-2023				1	0	3	0			
7	NA		10-11-2023				1	0	0	0		Textual Information(1)	
8	NA		09-09-2025				1	0	0	0		Textual Information(2)	
9	NA		19-12-2025				1	0	0	0		Textual Information(3)	

**Text Block**

Textual Information(1)	Foreign Director
Textual Information(2)	Foreign Director
Textual Information(3)	Foreign Director

Audit Committee Details							
Whether the Audit Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	01365405	Indrajit Banerjee	Non-Executive - Independent Director	Chairperson	13-11-2018		
2	09279899	Ashok Pandit	Non-Executive - Non Independent Director	Member	30-10-2023		
3	00106054	Suvalaxmi Chakraborty	Non-Executive - Independent Director	Member	13-11-2018		

Nomination and remuneration committee							
Whether the Nomination and remuneration committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	00106054	Suvalaxmi Chakraborty	Non-Executive - Independent Director	Chairperson	27-06-2025		
2	01365405	Indrajit Banerjee	Non-Executive - Independent Director	Member	13-11-2018		
3	10348774	Prem Kumar Nair	Non-Executive - Non Independent Director	Member	10-11-2023		

Stakeholders Relationship Committee							
Whether the Stakeholders Relationship Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	01365405	Indrajit Banerjee	Non-Executive - Independent Director	Chairperson	13-11-2018		
2	02775637	Ashutosh Raghuvanshi	Executive Director	Member	27-07-2021		
3	09279899	Ashok Pandit	Non-Executive - Non Independent Director	Member	27-06-2025		

Risk Management Committee							
Whether the Risk Management Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	01764813	Leo Puri	Non-Executive - Independent Director	Chairperson	27-06-2025		
2	02775637	Ashutosh Raghuvanshi	Executive Director	Member	15-10-2020		
3	02148022	Dilip Kadambi	Non-Executive - Non Independent Director	Member	29-09-2023		
4	03551067	Bishnu Prasad Panigrahi	Head Group Medical Strategy and Operations	Member	15-10-2020		Textual Information(1)
5	02407380	Anil Vinayak	Group Chief Operating Officer	Member	15-10-2020		Textual Information(2)

**Sr Text Block**

Textual Information(1)	Pursuant to the provisions of Regulation 21 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws, Risk Management Committee of the Company is constituted with following members: 1. Mr. Dilip Kadambi, Non-Executive Director, Member 2. Dr. Ashutosh Raghuvanshi, MD & CEO, Member 3. Mr. Anil Vinayak, Group Chief Operating Officer, Member 4. Dr. Bishnu Panigrahi, Head - Group Medical Strategy and Operations, Member 5. Leo Puri, Non-Executive Independent Director, Chairperson
Textual Information(2)	Pursuant to the provisions of Regulation 21 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws, Risk Management Committee of the Company is constituted with following members: 1. Mr. Dilip Kadambi, Non-Executive Director, Member 2. Dr. Ashutosh Raghuvanshi, MD & CEO, Member 3. Mr. Anil Vinayak, Group Chief Operating Officer, Member 4. Dr. Bishnu Panigrahi, Head - Group Medical Strategy and Operations, Member 5. Leo Puri, Non-Executive Independent Director, Chairperson

Corporate Social Responsibility Committee							
Whether the Corporate Social Responsibility Committee has a Regular Chairperson					No		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	02775637	Ashutosh Raghuvanshi	Executive Director	Member	27-07-2021		
2	01365405	Indrajit Banerjee	Non-Executive - Independent Director	Member	13-11-2018		
3	09279899	Ashok Pandit	Non-Executive - Non Independent Director	Member	27-06-2025		

<b>Other Committee</b>						
Sr	DIN Number	Name of Committee members	Name of other committee	Category 1 of directors	Category 2 of directors	Remarks

**Annexure 1****Annexure 1****III. Meeting of Board of Directors**

Disclosure of notes on meeting of board of directors explanatory								
Sr. No.	Date(s) of meeting (if any) in the previous quarter	Date(s) of meeting (if any) in the current quarter	Maximum gap between any two consecutive (in number of days)	Notes for not providing Date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors as on date of the meeting	Number of Directors present* (All directors including Independent Director)	No. of Independent Directors attending the meeting*
1	01-10-2025				Yes	9	6	2
2	11-11-2025		40		Yes	9	9	3
3	26-11-2025		14		Yes	9	9	3
4		13-02-2026	78		Yes	9	6	3
5		19-03-2026	33		Yes	9	9	3

**Annexure 1**

**IV. Meeting of Committees**

Disclosure of notes on meeting of committees explanatory										
Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
1	Audit Committee	04-11-2025				Yes	3	3	2	0
2	Audit Committee	11-11-2025	6			Yes	3	3	2	0
3	Audit Committee	13-02-2026	93			Yes	3	3	2	0
4	Audit Committee	18-03-2026	32			Yes	3	3	2	0
5	Audit Committee	23-03-2026	4			Yes	3	3	2	0
6	Stakeholders Relationship Committee	11-11-2025				Yes	3	3	1	0

**Annexure 1**

**IV. Meeting of Committees**

Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
7	Stakeholders Relationship Committee	13-02-2026	93			Yes	3	2	1	0
8	Nomination and remuneration committee	11-11-2025				Yes	3	3	2	0
9	Nomination and remuneration committee	11-02-2026	91			Yes	3	3	2	0
10	Corporate Social Responsibility Committee	21-11-2025				Yes	3	3	1	0
11	Risk Management Committee	15-10-2025				Yes	3	3	1	2
12	Risk Management Committee	23-03-2026	158			Yes	3	3	1	2

**Annexure 1****V. Affirmations**

Sr	Subject	Compliance status (Yes/No)
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	Yes
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	Yes
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	Yes
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 1000 listed entities)	Yes
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	Yes

**Annexure 1**

Sr	Subject	Compliance status
1	Name of signatory	Mr. Satyendra Chauhan
2	Designation	Company Secretary and Compliance Officer

**Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)**

**I. Disclosure on website in terms of LODR Regulation**

<b>Sr</b>				
Sr	Item	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.	Web address
	As per regulation 46(2) of the LODR:			
1.1	Details of business	Yes		<a href="https://www.fortishealthcare.com/about-us">https://www.fortishealthcare.com/about-us</a>
1.2	Memorandum of Association and Articles of Association	Yes		<a href="https://www.fortishealthcare.com/investor/agm%202024/moa%20&amp;%20aoa_fortis%20healthcare%20limited">https://www.fortishealthcare.com/investor/agm%202024/moa%20&amp;%20aoa_fortis%20healthcare%20limited</a>
1.3	Brief profile of board of directors including directorship and full-time positions in body corporates	Yes		<a href="https://www.fortishealthcare.com/investors">https://www.fortishealthcare.com/investors</a>
2	Terms and conditions of appointment of independent directors	Yes		<a href="https://www.fortishealthcare.com/investor/policies%20&amp;%20code/terms%20and%20conditions%20of%20appointment%20c">https://www.fortishealthcare.com/investor/policies%20&amp;%20code/terms%20and%20conditions%20of%20appointment%20c</a>
3	Composition of various committees of board of directors	Yes		<a href="https://www.fortishealthcare.com/investors/composition-of-committees/485">https://www.fortishealthcare.com/investors/composition-of-committees/485</a>
4	Code of conduct of board of directors and senior management personnel	Yes		<a href="https://www.fortishealthcare.com/investor/policies%20&amp;%20code/code%20of%20conduct">https://www.fortishealthcare.com/investor/policies%20&amp;%20code/code%20of%20conduct</a>
5	Details of establishment of vigil mechanism/ Whistle Blower policy	Yes		<a href="https://www.fortishealthcare.com/investor/policies%20&amp;%20code/whistle%20blower%20policy">https://www.fortishealthcare.com/investor/policies%20&amp;%20code/whistle%20blower%20policy</a>
6	Criteria of making payments to non-executive directors	Yes		<a href="https://www.fortishealthcare.com/investor/annual%20reports/fhl%20annual%20report%202024-25">https://www.fortishealthcare.com/investor/annual%20reports/fhl%20annual%20report%202024-25</a>
7	Policy on dealing with related party transactions	Yes		<a href="https://www.fortishealthcare.com/investor/policies%20&amp;%20code/policy%20on%20related%20party%20transactions">https://www.fortishealthcare.com/investor/policies%20&amp;%20code/policy%20on%20related%20party%20transactions</a>
8	Policy for determining 'material' subsidiaries	Yes		<a href="https://www.fortishealthcare.com/investor/policies%20&amp;%20code/policy%20on%20material%20subsidiary">https://www.fortishealthcare.com/investor/policies%20&amp;%20code/policy%20on%20material%20subsidiary</a>
9	Details of familiarization programmes imparted to independent directors	Yes		<a href="https://www.fortishealthcare.com/investor/familiarization%20programmes/familiarization%20program%202024-25">https://www.fortishealthcare.com/investor/familiarization%20programmes/familiarization%20program%202024-25</a>
10	Email address for grievance	Yes		<a href="https://www.fortishealthcare.com/investor/grievance%20redressal/grievance%20redressal">https://www.fortishealthcare.com/investor/grievance%20redressal/grievance%20redressal</a>

	redressal and other relevant details			
11	Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	Yes		<a href="https://www.fortishealthcare.com/investors">https://www.fortishealthcare.com/investors</a>
12	Financial results	Yes		<a href="https://www.fortishealthcare.com/investors/outcome-of-board-meeting/516">https://www.fortishealthcare.com/investors/outcome-of-board-meeting/516</a>
13	Shareholding pattern	Yes		<a href="https://www.fortishealthcare.com/investors/shareholding-pattern/498">https://www.fortishealthcare.com/investors/shareholding-pattern/498</a>
14	Details of agreements entered into with the media companies and/or their associates	NA		

**Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)**

**I. Disclosure on website in terms of LODR Regulation**

**Sr**

	As per regulation 46(2) of the LODR:		
15.1	(I) Schedule of analyst or institutional investor meet (II) Presentations prepared by the listed entity for analysts or institutional investors meet, post earnings or quarterly calls prior to beginning of such events.	Yes	<a href="https://www.fortishealthcare.com/investors/conference-call-invite/496">https://www.fortishealthcare.com/investors/conference-call-invite/496</a>
15.2	Audio recordings, video recordings, if any, and transcripts of post earnings or quarterly calls, by whatever name called, conducted physically or through digital means	Yes	<a href="https://www.fortishealthcare.com/investors/investor-presentations-&amp;-transcripts/494">https://www.fortishealthcare.com/investors/investor-presentations-&amp;-transcripts/494</a>
16	New name and the old name of the listed entity	NA	
17	Advertisements as per regulation 47 (1)	Yes	<a href="https://www.fortishealthcare.com/investors/newspaper-publications/521">https://www.fortishealthcare.com/investors/newspaper-publications/521</a>
18	Credit rating or revision in credit rating obtained	Yes	<a href="https://www.fortishealthcare.com/investors/credit-ratings/519">https://www.fortishealthcare.com/investors/credit-ratings/519</a>
19	Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year	Yes	<a href="https://www.fortishealthcare.com/investors/financials-of-subidiaries/478">https://www.fortishealthcare.com/investors/financials-of-subidiaries/478</a>
20	Secretarial Compliance Report	Yes	<a href="https://www.fortishealthcare.com/investors/annual-secretarial-compliance-report/482">https://www.fortishealthcare.com/investors/annual-secretarial-compliance-report/482</a>
21	Materiality Policy as per Regulation 30 (4)	Yes	<a href="https://www.fortishealthcare.com/investor/policies%20&amp;%20code/policy%20on%20determination%20of%20materiality%20of%20events%20&amp;">https://www.fortishealthcare.com/investor/policies%20&amp;%20code/policy%20on%20determination%20of%20materiality%20of%20events%20&amp;</a>

22	Disclosure of contact details of KMP who are authorized for the purpose of determining materiality as required under regulation 30(5)	Yes	<a href="https://www.fortishealthcare.com/investors">https://www.fortishealthcare.com/investors</a>
23	Disclosures under regulation 30(8)	Yes	<a href="https://www.fortishealthcare.com/investors/disclosure-under-reg.-30-of-sebi-(lodr)/513">https://www.fortishealthcare.com/investors/disclosure-under-reg.-30-of-sebi-(lodr)/513</a>
24	Statements of deviation(s) or variations(s) as specified in regulation 32	NA	
25	Dividend Distribution policy as per Regulation 43A(1)	Yes	<a href="https://www.fortishealthcare.com/investor/policies%20%20code/dividend%20distribution%20policy">https://www.fortishealthcare.com/investor/policies%20%20code/dividend%20distribution%20policy</a>
26.1	Annual return as provided under section 92 of the Companies Act, 2013	Yes	<a href="https://www.fortishealthcare.com/investors/annual-return/479">https://www.fortishealthcare.com/investors/annual-return/479</a>
26.2	Employee Benefit scheme documents framed in terms of SEBI (SBEB) Regulations, 2021	Yes	<a href="https://www.fortishealthcare.com/investor/miscellaneous/esop%20scheme-2026-approved%20by%20shareholders">https://www.fortishealthcare.com/investor/miscellaneous/esop%20scheme-2026-approved%20by%20shareholders</a>
27	Confirmation that the above disclosures are in a separate section as specified in regulation 46(2)	Yes	<a href="https://www.fortishealthcare.com/investors">https://www.fortishealthcare.com/investors</a>
28	Compliance with regulation 46(3) with respect to accuracy of disclosures on the website and timely updating	Yes	<a href="https://www.fortishealthcare.com/investors">https://www.fortishealthcare.com/investors</a>

**Annexure II****II. Annual Affirmations**

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
1	Independent director(s) have been appointed in terms of specified criteria of 'independence' and/or 'eligibility'	16(1)(b)	Yes	
2	Board composition	17(1), 17(1A) & 17(1C), 17(1D) & 17(1E)	Yes	
3	Meeting of Board of directors	17(2)	Yes	
4	Quorum of Board meeting	17(2A)	Yes	
5	Review of Compliance Reports	17(3)	Yes	
6	Plans for orderly succession for appointments	17(4)	Yes	
7	Code of Conduct	17(5)	Yes	
8	Fees/compensation	17(6)	Yes	
9	Minimum Information	17(7)	Yes	
10	Compliance Certificate	17(8)	Yes	

**Annexure II****II. Annual Affirmations**

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
11	Risk Assessment & Management	17(9)	Yes	
12	Performance Evaluation of Independent Directors	17(10)	Yes	
13	Recommendation of Board	17(11)	Yes	
14	Maximum number of Directorships	17A	Yes	
15	Composition of Audit Committee	18(1)	Yes	
16	Meeting of Audit Committee	18(2)	Yes	
17	Role of Audit Committee and information to be reviewed by the audit committee	18(3)	Yes	
18	Composition of nomination & remuneration committee	19(1) & (2)	Yes	
19	Quorum of Nomination and Remuneration Committee meeting	19(2A)	Yes	
20	Meeting of Nomination and Remuneration Committee	19(3A)	Yes	

**Annexure II****II. Annual Affirmations**

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
21	Role of Nomination and Remuneration Committee	19(4)	Yes	
22	Composition of Stakeholder Relationship Committee	20(1), 20(2) & 20(2A)	Yes	
23	Meeting of Stakeholders Relationship Committee	20(3A)	Yes	
24	Role of Stakeholders Relationship Committee	20(4)	Yes	
25	Composition and role of risk management committee	21(1),(2),(3),(4)	Yes	
26	Meeting of Risk Management Committee	21(3A)	Yes	
27	Quorum of Risk Management Committee meeting	21(3B)	Yes	
28	Gap between the meetings of the Risk Management Committee	21(3C)	NA	
29	Vigil Mechanism	22	Yes	
30	Policy for related party Transaction	23(1), (1A), (5), (6), & (8)	Yes	

**Annexure II****II. Annual Affirmations**

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
31	Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes	
32	Approval for material related party transactions	23(4)	Yes	
33	Disclosure of related party transactions on consolidated basis	23(9)	Yes	
34	Composition of Board of Directors of unlisted material Subsidiary	24(1)	Yes	
35	Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3),(4), (5) & (6)	Yes	
36	Alternate Director to Independent Director	25(1)	NA	
37	Maximum Tenure	25(2)	Yes	
38	Appointment, Re-appointment or removal of an Independent Director through special resolution or the alternate mechanism	25(2A)	Yes	
39	Meeting of independent directors	25(3) & (4)	Yes	
40	Familiarization of independent directors	25(7)	Yes	

**Annexure II****II. Annual Affirmations**

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
41	Declaration from Independent Director	25(8) & (9)	Yes	
42	Directors and Officers insurance	25(10)	Yes	
43	Confirmation with respect to appointment of Independent Directors who resigned from the listed entity	25(11)	Yes	
44	Memberships in Committees	26(1)	Yes	
45	Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes	
46	Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes	
47	Approval of the Board and shareholders for compensation or profit sharing in connection with dealings in the securities of the listed entity	26(6)	Yes	
48	Vacancies in respect Key Managerial Personnel	26A(1) & 26A(2), 26A(3)	Yes	
	Any other information to be provided - Add Notes			

**Annexure II**

1	Name of signatory	Mr. Satyendra Chauhan
2	Designation	Company Secretary and Compliance Officer

**Annexure II**

**III. Affirmations**

<b>Sr</b>	<b>Particulars</b>	<b>Compliance status (Yes/No/NA)</b>
1	The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied	Yes
	Any other information to be provided	

**Annexure II**

1	Name of signatory	Mr. Satyendra Chauhan
2	Designation	Company Secretary and Compliance Officer

<b>Additional Half yearly Disclosure DISCLOSURE OF LOANS / GUARANTEES / COMFORT LETTERS / SECURITIES ETC. (applicable only for half-yearly filings)</b>			
Any Other Information for Disclosure of Loans / Guarantees / Comfort Letters / Securities Etc.			Textual Information(1)
<b>I. Disclosure of Loans/ guarantees/comfort letters /securities etc. Refer note below</b>			
(A)Any loan or any other form of debt advanced by the listed entity directly or indirectly to			
Entity	Aggregate amount advanced during six months	Balance outstanding at the end of six months	
Promoter or any other entity controlled by them	0	6376599999	
Promoter Group or any other entity controlled by them	0	0	
Directors (including relatives) or any other entity controlled by them	0	0	
KMPs or any other entity controlled by them	0	0	
<b>(B) Any guarantee / comfort letter (by whatever name called) provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed By</b>			
Entity	Type (guarantee, comfort letter etc.)	Aggregate amount of issuance during six months	Balance outstanding at the end of six months(taking into account any invocation)
Promoter or any other entity controlled by them	0	0	0
Promoter Group or any other entity controlled by them	0	0	0
Directors (including relatives) or any other entity controlled by them	0	0	0
KMPs or any other entity controlled by them	0	0	0
<b>(C) Any security provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed by</b>			
Entity	Type of security (cash, shares etc.)	Aggregate value of security provided during six months	Balance outstanding at the end of six months
Promoter or any other entity controlled by them	0	0	0
Promoter Group or any other entity controlled by them	0	0	0
Directors (including relatives) or any other entity controlled by them	0	0	0
KMPs or any other entity controlled by them	0	0	0
(D) Additional Information			Textual Information(2)
<b>II. Affirmations</b>			
Affirmations		Compliance Status	Company Remarks
All loans (or other form of debt), guarantees, comfort letters (by whatever name called) or securities in connection with any loan(s) (or other form of debt) given directly or indirectly by the listed entity to promoter(s), promoter group, director(s) (including their relatives), key managerial personnel (including their relatives) or any entity controlled by them are in the economic interest of the company.		Yes	Textual Information(3)
Name	Vivek Kumar Goyal		
Designation	CFO		
Place	Gurugram		
Date	28-04-2026		

**Text Block**

Textual Information(2)

The amount of Rs. 6376599999/- includes : (A) Intercompany deposits given to entities related to erstwhile promoters- Rs. 44,503 lacs. (Including Interest accrued up to March 31, 2018) (B) Intercompany deposits given for settlement of outstanding loans of certain parties including erstwhile promoters towards part funding of a property in Birdie & Birdie Realtors Private Limited, (FHL Group Company) the valuation of which is under investigation- Rs. 12,275 lacs. Consequent to NCLT Orders received during the current year ended March 31, 2026, Birdie & Birdie Realtors Private Limited has been merged with Fortis Hospitals Limited (FHL Group Company). Accordingly, aforesaid amount of Rs. 12,275 lacs has been eliminated in the books of account being Intercompany deposits. (C) Intercompany deposits to subsidiaries for repayment of outstanding loans of entities related to erstwhile promoter- Rs. 1,010 lacs. Out of it, consequent to NCLT Orders received during the current year ended March 31, 2026, Fortis Emergency Services Limited (FHL Group Company) has been merged with Fortis Hospitals Limited. Accordingly, an amount of Rs. 215 lacs has been eliminated in the books of account being Intercompany deposits.

<b>Details of Cyber security incidence</b>		
Whether as per Regulation 27(2)(ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data or documents during the quarter		No
Number of cyber security incidence or breaches or loss of data event occurred during the quarter		
Sr.	Date of the event	Brief details of the event

**Signatory Details**

Name of signatory	Mr. Satyendra Chauhan
Designation of person	Company Secretary and Compliance Officer
Place	Gurugram
Date	28-04-2026

<b>Investor Grievance Details</b>	
No. of investor complaints pending at the beginning of Quarter	0
No. of investor complaints received during the Quarter	0
No. of investor complaints disposed off during the Quarter	0
No. of investor complaints those remaining unresolved at the end of the Quarter	0

**Disclosure of Imposition of Fine or Penalty The details of imposition of fine or penalty during the quarter in terms of sub-para 20 of para A of Part A of Schedule III are given below:**

Any Other Information for Disclosure of Imposition of Fine or Penalty					
Sr. No.	Name of the authority	Nature and details of the action(s) taken or order(s) passed	Date of receipt of direction or order, including any ad interim or interim orders, or any other communication from the authority	Details of the violation(s)/ contravention(s) committed or alleged to be committed	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible
1	Income Tax	Penalty u/s 270A of Rs.5,99,217 on account of disallowance of expense in assessment order for assessment year 2017-18	25-03-2026	Penalty is pursuant to disallowance of expense as made by A.O. in assessment order for assessment year 2017-18.	599217

**Disclosure of Updates to Ongoing Tax Litigations or Disputes The updates on tax litigations or disputes in terms of sub-para 8 of para B of Part A of Schedule III read with corresponding provisions of Annexure 18 of the Master Circular are given below:**

Any Other Information for Disclosure of Updates to Ongoing Tax Litigations or Disputes				
Sr. No.	Name of the opposing party	Date of initiation of the litigation / dispute	Status of the litigation / dispute as per last disclosure	Current status of the litigation / dispute
1	Income Tax Department	09-08-2021	On appeal by the Company (Fortis Hospitals Limited) for Assessment Year 2017-18, Case was referred to Transfer Pricing Officer (TPO) for Transfer Pricing (TP) Assessment. TPO has passed order on 29.01.2021 with no adverse inference. Later on, Assessing Officer (AO) has passed assessment order dt. 09.08.2021 making disallowances: -Rs.3,26,81,835 u/s 14A -Rs.28,96,72,142 - unexplained cash credit u/s 68 computed as per section 115BBE @ 60%. Amount under litigation is Rs. 26,56,61,808 and the matter is currently pending before Commissioner of Income Tax (Appeals).	No Change
2	Income Tax Department	29-09-2021	On appeal by the Company (Fortis Hospitals Limited) for Assessment Year 2019-20, Assessment was completed vide order dated 29.09.2021 making disallowances on account of: -14A r.w Rule 8D at Rs.5,37,26,805/- -Disallowance of bad debts at Rs.25,49,02,000/- - Advances from customers/patients at Rs.42,65,12,000/- -Disallowance of ICDs based on SEBI orders at Rs.402,43,62,000/- Assessing income at Rs.108,58,49,650/- as against loss at Rs.367,36,53,160/- Amount under litigation is Rs. 44,04,72,119 and the matter is currently pending before Commissioner of Income Tax (Appeals).	No change
3	Income Tax Department	11-02-2019	On appeal by the Company (Fortis Hospotel Limited) for Assessment Year 2015-16, Case was referred to Transfer Pricing Officer (TPO) for Transfer Pricing (TP) Assessment. TPO has passed order proposing adjustment. Later on, Assessing Officer (AO) has passed assessment order confirming the adjustment proposed in TP Order, being interest amount paid on Compulsorily Convertible Debentures (CCDs) issued by the company. Amount under litigation is Rs. 71,18,64,960 and the matter is currently pending before Commissioner of Income Tax (Appeals).	No change
4	Income Tax Department	03-06-2021	On appeal by the Company (Fortis Hospotel Limited) for Assessment Year 2017-18, Case was referred to Transfer Pricing Officer (TPO) for Transfer Pricing (TP) Assessment. TPO has passed order proposing adjustment. Later on, Assessing Officer (AO) has passed assessment order confirming the adjustment proposed in TP Order, being interest amount paid on Compulsorily Convertible Debentures (CCDs) issued by the company. Amount under litigation is Rs. 56,11,28,717 and the matter is currently pending before Commissioner of Income Tax (Appeals).	No change
5	Income Tax Department	24-11-2021	On appeal by the Company (Fortis Hospotel Limited) for Assessment Year 2018-19, Case was referred to Transfer Pricing Officer (TPO) for Transfer Pricing (TP) Assessment. TPO has passed order on 30.07.2021 proposing adjustment amounting to INR 74.63 Cr which is interest expense claimed on Compulsorily Convertible Debentures (CCDs) issued by the company to FGHIPL and consultancy expenses on the same. Later on, Assessing Officer (AO) has passed assessment order dt. 24.11.2021 confirming the adjustment proposed in TP Order. Amount under litigation is Rs. 33,26,19,748 and the matter is currently pending before Commissioner of Income Tax (Appeals).	No change
6	Income Tax Department	28-03-2005	In case of Escorts Heart Institute and Research Centre Limited, On appeal by the Department for Assessment Year 2001-02, Assessment was done u/s 143(1)(a) on 29.08.2002. The Assessing Officer reopened the assessment and passed the assessment order dated 28.03.2005 making an addition of Rs.149.09 crores. The Assessing Officer held that registration of a society as a company under Part IX of the Companies Act tantamount to a transfer of assets and hence alleged addition on account of capital gain has been made. Company's appeal allowed by Income tax appellate tribunal, revenue has filed appeal before Delhi High Court. Amount under litigation is Rs. 1,05,32,00,000 and the matter is currently pending before Delhi High Court.	No change
7	Income Tax Department	15-02-2017	In case of International Hospital Limited for Assessment Year 2013-14, Case was referred to Transfer Pricing Officer (TPO) for Transfer Pricing (TP) Assessment. TPO has passed order on 31.10.2016 proposing adjustment amounting to INR 569 million which is interest expense claimed on Compulsorily Convertible Debentures (CCDs) issued by the company to FGHIPL. Later on, Assessing Officer (AO) has passed assessment order dt. 15.02.2017 confirming the adjustment proposed in TP Order and also making disallowance u/s 14A read with rule 8D amounting to INR 60 million and u/s 36(i)(va) amounting to INR 0.26 million. An appeal filed before the Commissioner of Income-tax	No change

			(Appeals), New Delhi on 30.03.2017 has been decided. Further appeal filed before ITAT on 18.04.2019. Departmental also in appeal. Demand raised at Rs.15,01,91,860/- vide order passed u/s 143(3), the same was revised at Rs.34,18,72,340/- vide order dated 17.05.2018 passed u/s 154. Amount under litigation is Rs. 34,18,72,340/- and the matter is currently pending before Income Tax Appellate Tribunal	
8	Income Tax Department	10-05-2021	In case of International Hospital Limited for Assessment Year 2017-18, Case was referred to Transfer Pricing Officer (TPO) for Transfer Pricing (TP) Assessment. TPO has passed order dated 11.01.2021 proposing adjustment of Rs.92,83,08,762/-. Later on, Assessing Officer (AO) has passed assessment order u/s 143(3) dated 10.05.2021 confirming the adjustment proposed in TP Order and making further disallowance u/s 36(1)(iii) at Rs.71,00,77,700/- and u/s 36(1)(va) at Rs.9,05,271/- thereby raising a demand of Rs.39.89Cr. Amount under litigation is Rs. 39,89,16,838/- and the matter is currently pending before Commissioner of Income Tax (Appeals).	No change
9	Income Tax Department	25-11-2021	In case of International Hospital Limited for Assessment Year 2018-19, Case was referred to Transfer Pricing Officer (TPO) for Transfer Pricing (TP) Assessment. TPO has passed order dated 30.07.2021 proposing adjustment of Rs.228,08,64,295/-. Later on, Assessing Officer (AO) has passed assessment order u/s 143(3) dated 25.11.2021 confirming the adjustment proposed in TP Order and making disallowance u/s 36(1)(iii) at Rs.75,05,77,475/- and u/s 36(1)(va) at Rs.12,00,000/- thereby raising a demand of Rs.187.35Cr. Amount under litigation is Rs. 1,87,35,22,640 and the matter is currently pending before Commissioner of Income Tax (Appeals).	No change
10	Income Tax Department	21-03-2024	Fortis Hospitals Limited, a material subsidiary of the Company has received an Income tax assessment order for Assessment Year 2022-23 (Financial Year 2021-22), wherein a demand of Rs.89.53 Crores (including interest of Rs.9.54 Crores) has been raised. The matter is currently pending before Commissioner of Income Tax (Appeals).	No change
11	Office of the Principal Commissioner” GST, Gurugram,	18-07-2024	GST Department of Haryana has issued Show Cause Notice alleging that the company i.e. Fortis Hospitals Limited is charging MRP from IPD patient for medicine, consumable and implant which include GST and not remitting the same to government exchequer. Thus, the subsidiary Company i.e. Fortis Hospitals Limited has filed the writ petition by challenging the show cause notice issued by the- Office of the Principal Commissioner GST, Gurugram. Amount under Litigation is Rs.61.19 Crore plus interest and penalty and the matter is currently pending before Punjab and Haryana High Court.	No change
12	Income Tax Department	03-04-2025	In case of International Hospital Limited, Income Tax Demand order amounting to Rs.76,19,13,970/- has been raised to IHL vide Order under Section 147/143(3)/144C read with Section 144B of the Income Tax Act, 1961 in respect of Assessment year 2019-20 (Financial year 2018-19). An Appeal before Commissioner of Income Tax (Appeals) has been filed on 30.04.2025 and the same is currently pending.	No change
13	The Office of Commissioner, CGST, Audit-I, CR Building, IP Estate, New Delhi	29-09-2025	GST Department of Delhi has issued Show Cause Notice alleging that the company i.e. Escorts Heart Institute and Research Centre Limited is charging MRP from IPD patient for medicine or drugs and consumable which include GST and not remitting the same to government exchequer. Thus, the subsidiary Company i.e. Escorts Heart Institute and Research Centre Limited has filed the writ petition by challenging the show cause notice issued by the- Office of the Commissioner CGST, Audit-I, Delhi. Amount under Litigation is Rs.6.66 Crore plus interest and penalty and the matter is currently pending before Delhi High Court.	Delhi High Court ("HC") has issued Hearing Order dated 19.12.2025 wherein HC has directed to the Company to file reply to SCN before GST department of Delhi. Reply filed with GST Authority and order passed confirming the demand subject to final adjudication by Delhi HC.
14	State Tax Officer (ST)- Group IX, Chengalpattu Intelligence Division, Tamil Nadu-603101	29-12-2025	In case of Fortis Health Management Limited, GST Department of Tamil Nadu has issued GST Order for FY 2020-21, wherein GST department has denied the exemption on supply of healthcare services. The Company is in process of filing appeal before GST Fist Appellate Authority. Amount under litigation is Rs.1.68 Crore along with Interest of Rs.1.42 Crore & penalty of Rs.1.68 Crore has been raised.	Appeal filed on 10th March 26
15	State Tax Officer (ST)- Group IX, Chengalpattu Intelligence Division, Tamil Nadu-603101	29-12-2025	In case of Fortis Health Management Limited, GST Department of Tamil Nadu has issued GST Order for FY 2021-22, wherein GST department has denied the exemption on supply of healthcare services. The Company is in process of filing appeal before GST Fist Appellate Authority. Amount under litigation is Rs.3.19 Crore along with Interest of Rs.2.17 Crore & penalty of Rs.3.19 Crore has been raised.	Appeal filed on 10th March 26
16	State Tax Officer (ST)- Group IX, Chengalpattu Intelligence Division, Tamil Nadu-603101	29-12-2025	In case of Fortis Health Management Limited, GST Department of Tamil Nadu has issued GST Order for FY 2022-23, wherein GST department has denied the exemption on supply of healthcare services. The Company is in process of filing appeal before GST Fist Appellate Authority. Amount under litigation is Rs.3.26 Crore along with Interest of Rs.1.59 Crore & penalty of Rs.3.26 Crore has been raised.	Appeal filed on 09th March 26
17	Income Tax Department	27-03-2026	Income Tax Authority has issued assessment order dated 27.03.2026 for AY 2024-25 wherein demand of INR 117.04 Crores has been raised. The	Appeal to be filed

			Company is evaluating all options including filing an appeal and rectification application against the said order.	
18	State Tax Officer (ST)- Group IX, Chengalpattu Intelligence Division, Tamil Nadu-603101	02-01-2026	GST Authority had issued show cause notice for an amount of INR 570.00 lakhs (including penalty of INR 285.00 lakhs) for the FY 2023-24. On submission of response by the Company, GST Authority has passed order and confirmed demand of INR 597.93 lakhs (including interest & penalty of INR 79.29 lakhs & INR 259.32 lakhs respectively). The show cause notice in relation to balance amount has been dropped.	Appeal to be filed
19	Income Tax Department	27-03-2026	Income Tax Authority has issued assessment order dated 27.03.2026 for A.Y. 2021-22 wherein demand of INR 149.12 Crores has been raised. The Company is evaluating all options including filing an appeal and rectification application against the said order.	Appeal to be filed
20	DCIT	30-11-2018	Disposed off in favour of assessee by Order of CIT (A), dated 27.05.2024. However DCIT, Income Tax – Gurugram filed an appeal before ITAT. Now the matter is pending with ITAT.	Disposed off in favour of assessee by Order of ITAT, dated 22/07/2025.
21	DCIT	19-01-2018	Pending before CIT(A) / NFAC	Pending before CIT(A) / NFAC
22	DCIT	18-01-2019	Pending before CIT(A) / NFAC	Pending before CIT(A) / NFAC
23	DCIT	30-06-2020	Pending before CIT(A) / NFAC	Pending before CIT(A) / NFAC

